All In Biotech

Drug Trial Radar · NCT06304740

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of a Single Subcutaneous Dose of IMG-007 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

16

Actual

Start

Mar 6, 2024

Primary completion

Aug 28, 2024

Study completion Aug 28, 2024

Sponsor

Lead sponsor
Inmagene LLCIndustry
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose.

Conditions

  • Healthy Volunteers

Interventions

  • IMG-007Drug

    Subcutaneous injection of IMG-007

  • PlaceboDrug

    Subcutaneous Injection of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event EvaluationTime frame: Up to 18 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research

    Perth, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.